You are here: Industry Insights > TJM2

News List

I-Mab Release Results for Anti-GM-CSF Antibody TJM2 to Treat CRS-Related COVID-19 americanpharmaceuticalreview
June 03, 2020
I-Mab announced interim results from a multi-center, double blinded, randomized, placebo-controlled, three-arm clinical study of TJM2 in patients with cytokine release syndrome (CRS) associated with severe coronavirus disease 2019 (COVID-19).
I-Mab Announces IND Clearance to Treat COVID-19 Cytokine Release Syndrome americanpharmaceuticalreview
April 09, 2020
I-Mab announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) to initiate clinical study for TJM2.
I-Mab Explores TJM2 in Treating Severe COVID-19 Disease contractpharma
March 16, 2020
Clinical study will explore the potential of TJM2, a mAb against Cytokine Release Syndrome, which is an overreaction of the immune system caused by inflammation.
I-Mab to Develop TJM2 for Cytokine Release Syndrome Patients with COVID-19 americanpharmaceuticalreview
March 16, 2020
I-Mab Biopharma is initiating the development of TJM2 (TJ003234) to treat cytokine storm in severe and critically ill patients caused by the coronavirus disease (COVID-19).
I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China En-CPhI.CN
November 15, 2019
I-Mab Biopharma, a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and ...